Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

News   May 24, 2018 | Original story from University of Texas Health

 
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

Working on a promising treatment for facial tumors tied to tuberous sclerosis complex, from the left, are Adelaide Hebert, M.D.; John Slopis, M.D.; Mary Kay Koenig, M.D.; Joshua Samuels, M.D., M.P.H.; and Hope Northrup, M.D. All are from McGovern Medical School at UTHealth in Houston with the exception of Slopis, who is with The University of Texas MD Anderson Cancer Center. Credit: Maricruz Kwon, UTHealth

 
 
 

RELATED ARTICLES

PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.

READ MORE

Simple Sugar Prevents Neurodegeneration in Lysosomal Storage Disease

News

New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)

READ MORE

Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass Spec

News

Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy